EGFR mutation + BRAF V600E
|
CRC
|
EGFR mutation + BRAF V600E
|
CRC
|
cetuximab + alpelisib + encorafenib Resistant: C3 – Early Trials
|
cetuximab + alpelisib + encorafenib Resistant: C3 – Early Trials
|
EGFR mutation + BRAF V600E
|
CRC
|
EGFR mutation + BRAF V600E
|
CRC
|
cetuximab + encorafenib + binimetinib Resistant: C3 – Early Trials
|
cetuximab + encorafenib + binimetinib Resistant: C3 – Early Trials
|
EGFR mutation + BRAF V600E
|
CRC
|
EGFR mutation + BRAF V600E
|
CRC
|
cetuximab + encorafenib Resistant: C3 – Early Trials
|
cetuximab + encorafenib Resistant: C3 – Early Trials
|
EGFR mutation + BRAF V600E
|
NSCLC
|
EGFR mutation + BRAF V600E
|
NSCLC
|
trametinib + osimertinib + dabrafenib Sensitive: C4 – Case Studies
|
trametinib + osimertinib + dabrafenib Sensitive: C4 – Case Studies
|
EGFR mutation + BRAF V600E
|
LUAD
|
EGFR mutation + BRAF V600E
|
LUAD
|
trametinib + erlotinib Sensitive: D – Preclinical
|
trametinib + erlotinib Sensitive: D – Preclinical
|
EGFR mutation + BRAF V600E
|
LUAD
|
EGFR mutation + BRAF V600E
|
LUAD
|
erlotinib Resistant: D – Preclinical
|
erlotinib Resistant: D – Preclinical
|